Design Therapeutics Launches with $45M to Advance Therapy Candidates for FA and Other Disorders

Print Friendly, PDF & Email

FRIEDRICH’S ATAXIA NEWS: Design Therapeutics has launched with $45 million in funding to advance its lead candidate for the treatment of Friedreich’s ataxia into clinical development, and support programs for other nucleotide repeat disorders such as fragile X syndrome , and myotonic dystrophy . These genetic diseases are caused by excessive repeats […]